NCT02374645 - A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

February 18, 2018

Study Completion Date

September 14, 2018

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

Volitinib

600mg or 800mg QD: Patients may continue to receive the treatment as long as they are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.

DRUG

gefitinib

250mg QD: Patients may continue to receive the treatment as long as they are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.

Trial Locations (1)

510080

Guangdong General Hospital, Guangzhou